Literature DB >> 22698433

Biological variation of INR in stable patients on long-term anticoagulation with warfarin.

Anton M H P van den Besselaar1, Paola Fogar, Vittorio Pengo, Gualtiero Palareti, Simon Braham, Marco Moia, Armando Tripodi.   

Abstract

Within-individual biological variation of INR (CV(B)) was assessed in 245 selected stable warfarin-treated patients monitored by three thrombosis centers. Selection criteria were: treatment period of six months or longer before the observation period; at least six consecutive INRs within the therapeutic range of 2.0 - 3.0; interval between consecutive INR measurements of two weeks or longer; no change in warfarin dose; no changes in the patient's circumstances which may influence the INR, such as intercurrent diseases, invasive procedures, starting or stopping drugs interacting with warfarin. The minimum, maximum and mean within-individual coefficient of variation CV(B) of the INR measurements in the 245 selected patients were 0.4%, 14.5%, and 9.0%, respectively Analytical performance goals for the INR measurement (imprecision) could be derived from the mean CV(B). For a therapeutic range of 2.0 - 3.0 with warfarin, the desirable and optimum imprecision of INR determination is <4.5% CV and <2.25% CV, respectively. The biological variation and analytical performance goals have been derived using classic laboratory methods but should be applicable to point-of-care testing as well.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22698433     DOI: 10.1016/j.thromres.2012.05.028

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  3 in total

Review 1.  Antithrombotic dose: Some observations from published clinical trials.

Authors:  Simon B Dimmitt; Christopher N Floyd; Robin E Ferner
Journal:  Br J Clin Pharmacol       Date:  2019-07-01       Impact factor: 4.335

2.  CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.

Authors:  Paulo Caleb Junior Lima Santos; Carla Luana Dinardo; Isolmar Tadeu Schettert; Renata Alonso Gadi Soares; Liz Kawabata-Yoshihara; Isabela Martins Bensenor; José Eduardo Krieger; Paulo Andrade Lotufo; Alexandre Costa Pereira
Journal:  Eur J Clin Pharmacol       Date:  2012-09-19       Impact factor: 2.953

3.  Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects.

Authors:  Dagmar Kubitza; Michael Becka; Wolfgang Mück; Jöern Krätzschmar
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.